Man's Best Friend in More Ways Than One The Comparative Oncology Program was featured in the CCR Corrections.
The CCOGC is now accepting applications for prospective collections. Please visit www.ccogc.net for more information and to access the application
April 12, 2010
Clarity to guide the development of new cancer drugs using a Comparative
The opportunity of a comparative and integrated approach to cancer drug development, through the use of pet dogs with cancer has now been implemented by many groups in the field. Indeed, this valued perspective has been considered to be an opportunity for a competitive advantage in the drug development communities.
Recent efforts have now clarified the regulatory perspective on this approach and contributed further to a guide on the optimal integration of Comparative Oncology in cancer drug development. Clarity has emerged from a meeting convened in June 2008 entitled “Translation of New Cancer Treatments from Canine to Human Cancer Patients” that led to a recently published manuscript in Clinical Cancer Research, "Guiding The Optimal Translation of New Cancer Treatments from Canine to Human Cancer Patients"
This guide has been reviewed favorably by the Center for Drug Evaluation and Research at the Food and Drug Administration (CDER-FDA). CDER affirmed their interest in new efforts to develop more effective oncology drugs and their interest in accepting as part of an IND submission package data from parallel treatments in companion animals as a guide in designing human clinical trials. CDER commented that the reporting requirements outlined in the guide were appropriate for such translational studies.
These reporting requirements will now streamline the implementation of the Comparative Approach to new cancer drug development.
For more information please contact Christina Mazcko at firstname.lastname@example.org
PLoS Medicine, Health In Action
The Health in Action section of PLoS medicine focuses on innovative health improvement projects. Recently, the Comparative Oncology Trials Consortium was highlighted for this section. The opportunities of the comparative approach to drug development are described and many of the perceived risks and limitations of the approach are addressed. We discuss the recent additions of the COTC pharmacodynamic core (PD core) to provide infrastructure and support for the development, validation, and assessment of pharmacokinetic, pharmacodynamic, and biological endpoints for clinical trials that are detailed and biologically intensive.
In this review, we present a theoretical financial model illustrating the potential benefit to the drug development process of using an
integrated comparative approach compared to a conventional approach and a look toward future opportunities of consortium and comparative oncology.